GenScript ProBio Opens China’s Largest Commercial GMP Plasmid Manufacturing Facility
8.12.2021 12:00:00 EET | Business Wire | Press release
GenScript ProBio announced today the opening of China's largest commercial GMP plasmid manufacturing facility during a ceremony at the site in Zhenjiang, Jiangsu Province. The 6,400-square-meter manufacturing plant enables GenScript ProBio to offer global customers a one-stop service for plasmids - from preclinical study (IIT), to investigational new drug (IND) filing, to clinical trial and commercial manufacturing - to accelerate the innovation and development of high-quality cell and gene therapy mRNA drugs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005385/en/
GenScript ProBio’s largest commercial GMP plasmid manufacturing facility in China opens in Zhenjiang, Jiangsu Province. (Photo: Business Wire)
As GenScript ProBio's second GMP plasmid manufacturing facility, the plant more than doubles the company's production capacity and strengthens its position as a leading CDMO. It enables the company to offer services including off-the-shelf LentiHelpTM plasmids, Pro grade plasmids for preclinical development, plasmids CMC study for IND filing, clinical GMP plasmids for early clinical trials, and cGMP plasmids for late-phase and commercialization.
The facility also expands GenScript ProBio's operations, which already included the largest commercial GMP plasmid manufacturing facility in China. GenScript ProBio is the first CDMO enterprise in China to have separate production facilities for plasmids and viral vectors. GenScript ProBio is the only GMP manufacturing platform in China that provides in vitro transcription (IVT) template linearized plasmids for mRNA vaccines.
In 2020, GenScript ProBio helped Suzhou Abogen secure the first clinical approval for an mRNA vaccine in China, and in October 2021, it reached an agreement with Abogen and Walvax for commercial manufacturing of the vaccine. Besides helping many mRNA vaccine enterprises in China obtain clinical approvals by NMPA, GenScript ProBio also supported companies in South Korea and the United States as they sought clinical approvals for mRNA vaccines in South Korea and Japan.
“GenScript ProBio adheres to the mission of‘Innovation through Collaboration.’Our extensive experience and high-quality plasmid viral vector manufacturing services have helped customers worldwide advance their clinical trials and commercial development programs," said Dr. Brian Min, CEO of GenScript ProBio, during a speech at the opening ceremony. "Our GMP plasmid manufacturing for mRNA vaccine development has also helped our customers in the fight against the COVID-19 pandemic."
Since its founding GenScript ProBio has supported the development of cell and gene therapies. In 2018, GenScript ProBio helped its subsidiary Legend Biotech secure the first CAR-T clinical approval in China. In 2019 and 2020, GenScript ProBio, as a service provider of Xiangxue, helped it secure the first TCR-T project approval from the NMPA, as well as approval from the FDA. The filing in China took only 54 working days from the submission of the IND application to the receipt of the Notification of Drug Clinical Trials, setting a record for the fastest new drug approval in 2019 in China.
About GenScript ProBio
GenScript ProBio is the biologics CDMO segment of GenScript Biotech, proactively providing end-to-end service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in antibody drug and gene and cell therapy to accelerate drug development for customers. https://www.genscriptprobio.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005385/en/
Contact information
Berkan Unal, Director Business Development
E-mail: berkan.unal@genscript.com
Phone: +49 176 233 22 401
Shanlin Yang, Media Relations Manager
E-mail: shanlin.yang@genscript.com
Phone: +86 150 7138 1167
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taktile Secures $110M in Goldman Sachs-led Series C to Power AI Transformation in Financial Institutions24.6.2026 16:30:00 EEST | Press release
Taktile, the leader in AI transformation for financial institutions, today announced its $110 million Series C fundraise. Growth Equity at Goldman Sachs Alternatives led the round, with participation from Balderton Capital, Index Ventures, Tiger Global, Y Combinator, and Dig Ventures. Taktile Fast Facts Taktile enables banks and insurers to transform into AI-native organizations that are increasingly powered by autonomous agents. Demand for Taktile accelerated in 2025, as AI models became capable of automating high-stakes decisions that previously required hours of manual work—from underwriting business loans and assessing claims to catching financial crime. Customers automate and optimize decisions with Taktile by combining its financial services expertise and product built for sector-specific AI use cases. One of the world’s largest insurers is running multiple use cases on Taktile, with projected cost efficiencies of over $90M in claims processing alone. Taktile’s team has a proven
New MetLife Study Reveals a 72% “Confidence Gap” in Ability to Recover from Life's Setbacks24.6.2026 16:25:00 EEST | Press release
A new multinational study from MetLife reveals a striking “confidence gap”: while most adults describe themselves as resilient, their confidence drops by 72% when faced with real-life setbacks. The Confident Pathways Report, conducted across the United States, United Kingdom, Japan, and Mexico, was designed to better understand how confidence is built and sustained throughout life. The findings underscore the role of opportunity, preparedness, and support in building confidence - factors that help people navigate uncertainty, recover from setbacks and pursue their goals. At a time when soccer is bringing people and communities together around the world, the findings also highlight how early childhood experiences such as sports, education, and mentorship can help foster resilience and gain confidence from a young age. Key findings across the four countries surveyed include: Confidence drops by 72% when adults consider their ability to recover from setbacks. Respondents were far more lik
StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide24.6.2026 16:08:00 EEST | Press release
StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624368623/en/ Developed as an alternative to traditional cell block methods, which convert concentrated cells suspended in fluid into a paraffin-embedded format for slide-based evaluation, the patent‑pending CytoPath Disc offers a more streamlined and efficient approach. The CytoPath Disc absorbs concentrated cells within a simple, sponge-like matrix, which is then processed, embedded, stained, and sectioned using standard histology workflows. Traditional cell block preparation methods often present challenges in achieving consistent results due to complex procedures, as well as the need for additional equipm
TensorX Launches With €8M Seed Funding Round Led by Darius Cubed Ventures for Bet on European Sovereign AI Infrastructure With Plans to Deploy up to €100M in NVIDIA Blackwell GPUs24.6.2026 16:07:00 EEST | Press release
A team of Irish founders has committed €8 million to Nvidia Blackwell GPUs, including the latest B300 chips, to launch TensorX, a sovereign AI inference platform designed for Europe's AI builders, trusted by regulated industries and already generating revenue from paying customers. The company was founded by Shane Morton, is part of the NVIDIA Inception program and is partnering with Dell on sourcing GPU hardware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528791384/en/ (From left to right): Craig Donnelly, Shane Morton, Nicole Morton, Tim Grant At a time when enterprises are racing to adopt artificial intelligence but most remain unwilling to let their data leave European jurisdiction, TensorX offers high-performance inference with zero data retention, running entirely on dedicated hardware in Dublin and Helsinki. TensorX is also in advanced talks around a financing facility to further expand its European footprint,
Clearwater Analytics Benchmarks Private Credit Strategy, Performance, and Risk Across Institutional Portfolios24.6.2026 16:00:00 EEST | Press release
Clearwater Analytics (NYSE: CWAN) today released Credit Where It’s Due: The Persistent Rise of Private Credit, its first comprehensive study of how private credit has reshaped institutional portfolios. The report draws on holdings and transactions data from the Clearwater platform, which spans $10 trillion in institutional assets across 60 asset classes. It documents private credit exposure, examines how the asset class has contributed to returns, and identifies where investment risks concentrate. The findings challenged a narrative centered on systemic contagion. Instead it found the systemic risks were idiosyncratic, concentrated on specific balance sheets that are largely hidden from investors without the right infrastructure. “At Clearwater, we are no strangers to the rise of private credit. Assets on our platform have grown nearly 20% over the last two years alone,” said Kirat Singh, President of Risk and Alternative Assets at Clearwater Analytics. “This report was born from what
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom